Watch BIIB. Know when insiders buy.
One email the day a filing lands. Free.
Work order
63
WATCH · shorts 63
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 1
buys / sells · latest disclosed Sep 1
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $32.6BP/E 23.7DIV YIELD —FCF YIELD 7.43%REV TTM $9.9B +1.2%NET INCOME $1.4B −7.3%NET DEBT $3.4B52W 135.67 – 224.51SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2026 · Mar 31 | $2.5B | +1.9% | 73.3% | — | $319.5M | +32.8% | 2.15 | $645.5M | $51.2M | $594.3M | Apr 29 |
| Q4 2025 · Dec 31derived | $2.3B | −7.1% | 78.3% | — | −$48.9M | −118.3% | -0.35 | $511.9M | $43.9M | $468M | Feb 6 |
| Q3 2025 · Sep 30 | $2.5B | +2.8% | 73.4% | — | $466.5M | +20.1% | 3.17 | $1.3B | $46.2M | $1.2B | Oct 30 |
| Q2 2025 · Jun 30 | $2.6B | +7.3% | 77.1% | — | $634.8M | +8.8% | 4.33 | $160.9M | $26.6M | $134.3M | Jul 31 |
| Q1 2025 · Mar 31 | $2.4B | +6.1% | 74.1% | — | $240.5M | −38.9% | 1.64 | $259.3M | $37.1M | $222.2M | Apr 29 |
| Q4 2024 · Dec 31derived | $2.5B | +2.9% | 76.2% | — | $266.7M | +6.8% | 1.83 | $760.9M | $39.3M | $721.6M | Feb 6 |
| Q3 2024 · Sep 30 | $2.5B | −2.5% | 74.1% | — | $388.5M | — | 2.66 | $935.6M | $35M | $900.6M | Oct 30 |
| Q2 2024 · Jun 30 | $2.5B | +0.4% | 77.8% | — | $583.6M | −1.4% | 4.00 | $625.8M | $33.5M | $592.3M | Jul 31 |
| Q1 2024 · Mar 31 | $2.3B | — | 76.3% | — | $393.4M | — | 2.70 | $553.2M | $45.9M | $507.3M | May 1 |
| Q4 2023 · Dec 31derived | $2.4B | — | 74.1% | — | $249.7M | — | 1.71 | $12.5M | $65.2M | −$52.7M | Feb 6 |
| Q3 2023 · Sep 30 | $2.5B | — | 73.9% | — | −$68.1M | — | -0.47 | $592.4M | $74.2M | $518.2M | Oct 30 |
| Q2 2023 · Jun 30 | $2.5B | — | 75.9% | — | $591.6M | — | 4.07 | $487M | $71M | $416M | Aug 1 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $9.9B | 75.7% | — | $1.3B | 13.1% | 8.79 | $2.2B | $153.8M | $2.1B | — | — |
| FY2024 · to Dec 31 | $9.7B | 76.1% | — | $1.6B | 16.9% | 11.18 | $2.9B | $153.7M | $2.7B | $0 | — |
| FY2023 · to Dec 31 | $9.8B | 74.2% | — | $1.2B | 11.8% | 7.97 | $1.5B | $277M | $1.3B | $0 | — |
| FY2022 · to Dec 31 | $10.2B | 77.6% | — | $3B | 29.9% | 20.87 | $1.4B | $240.3M | $1.1B | $750M | — |
| FY2021 · to Dec 31 | $11B | 80.8% | $2.8B | $1.6B | 14.2% | 10.40 | $3.6B | $258.1M | $3.4B | $1.8B | — |
| FY2020 · to Dec 31 | $13.4B | 86.6% | $4.6B | $4B | 29.8% | 24.80 | $4.2B | $424.8M | $3.8B | $6.7B | — |
Every number comes from BIOGEN INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.